Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 14/20 | 0.60 |
| ▸ | ALB | P02768 | 2/20 | 0.60 |
| ▸ | PDE6D | O43924 | 4/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | PMAIP1 | Q13794 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | BAD | Q92934 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30000879 | 1.00 | MCL1 (0.60) | MCL1ALBPDE6DBCL2PMAIP1 | |
| SCHEMBL29262070 | 0.99 | MCL1 (0.61) | MCL1ALBPDE6DBCL2PMAIP1 | |
| SCHEMBL30000975 | 0.94 | MCL1 (0.52) | MCL1ALBPDE6DBCL2STAT3 | |
| SCHEMBL24745226 | 0.94 | MCL1 (0.52) | MCL1ALBPDE6DBCL2STAT3 | |
| SCHEMBL24744625 | 0.92 | MCL1 (0.49) | MCL1ALBPDE6D | |
| SCHEMBL24745295 | 0.88 | MCL1 (0.51) | MCL1ALB | |
| SCHEMBL30000763 | 0.88 | MCL1 (0.51) | MCL1ALB | |
| SCHEMBL24744736 | 0.87 | MCL1 (0.50) | MCL1ALB | |
| SCHEMBL30000842 | 0.87 | MCL1 (0.50) | MCL1ALB | |
| SCHEMBL24745172 | 0.86 | PDE6D (0.46) | MCL1ALBPDE6DPTK2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |